NGM·Healthcare·$117M·#307 / 520 in Healthcare
RANI Rani Therapeutics Holdings, Inc
38HIGH RISK
CATEGORY BREAKDOWN
GROWTH84
QUALITY0
STABILITY56
VALUATION0
GOVERNANCE29
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+58.9%
84
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
12 months
40
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
13.1%
90
< 25% strong
Price / Sales
Market cap relative to trailing revenue
71.4x
0
< 3x strong
Rule of 40
Growth rate plus operating margin
-2287
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
5.6%
43
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+197.3%
0
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE RANI WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when RANI's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.